Novo Nordisk to Acquire Ocedurenone for Hypertension from KBP Biosciences
By Lalit Mishra
Pharma Deals Review: Vol 2023 Issue 10 (Table of Contents)
Published: 25 Oct-2023
DOI: 10.3833/pdr.v2023.i10.2826 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In a significant move towards entering the cardiovascular and chronic kidney disease space, Novo Nordisk has agreed to acquire late-stage investigational drug, ocedurenone, from KBP Biosciences for up to US$1...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS